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CASE REPORT
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Abstract
Brevibacterium casei is an extremely rare organism that can lead to peritonitis in End-stage renal disease patients of
peritoneal dialysis. Out of only ﬁve overall Brevibacterium species peritonitis reported worldwide, only two of them had
B. casei subspecies peritonitis detected, with both needing peritoneal dialysis catheter removal and change in dialysis
modality to hemodialysis. Our patient, an elderly 63-year-old Hispanic male, was on peritoneal dialysis at home and
presented with features suggestive of peritonitis. He was diagnosed subsequently with B. casei and started on broad
spectrum intraperitoneal antibiotics. However, he did not need dialysis modality change and recovered fully after 3
weeks of appropriate intraperitoneal antibiotics therapy. Longer antibiotics therapy and frequent clinical follow-up plus
better clinician awareness are needed to prevent this rare infection.
Keywords: Brevibacterium species, Peritonitis, Peritoneal dialysis, Brevibacterium casei, End-stage renal disease, Atypical
microorganism

1. Introduction

P

eritonitis is a serious, life-threatening complication of peritoneal dialysis (PD) that can lead
to signiﬁcant morbidity and mortality. It is caused
mostly by gram-positive organisms. Brevibacterium
casei, a gram-positive coryneform bacterium, an
atypical microorganism which is an extremely rare
cause of peritonitis in PD patients. B. casei has been
reported to cause relapsing peritonitis, sometimes
requiring removal of PD catheter and change of
modality of dialysis.

2. Case report
A 63-year-old Hispanic male with end-stage renal
disease (ESRD) on continuous cycler peritoneal
dialysis (CCPD) for the preceding two years,
presented to the peritoneal dialysis clinic with
complaints of low-grade fever for 2 days and diffuse

abdominal pain along with a cloudy peritoneal
dialysis efﬂuent. The abdominal pain was dull,
diffuse with moderate intensity. Each peritoneal
dialysis exchange led to pain. He had no associated
diarrhea, constipation, nausea, or vomiting. His past
medical history included diabetes mellitus, essential
hypertension, and end-stage renal disease. His
home medications were metoprolol succinate 50 mg
twice daily, calcitriol 0.5 mg daily, calcium acetate
667 mg tabs 2 tablets thrice daily with meals, glipizide 10 mg daily and long-acting insulin Lantus.
His CCPD modality consisted of four nighttime
exchanges with, 2.5 Liter(L) per exchange of 2.5%
dextrose solution, and 2 L of icodextrin daytime
dwell.
His clinic vital signs - temperature of 101 Fahrenheit (F), blood pressure 151/79 mm Hg, pulse rate 67
beats per minute, respiratory rate 17 breaths per
minute, room air oxygen saturation of 98%. Gastrointestinal system examination suggested diffuse
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tenderness with guarding but no rigidity, audible
bowel sounds, with a peritoneal dialysis catheter in
the right lower quadrant with no localized tenderness or visible discharge. All of the other remaining
systemic physical examination was unremarkable.
Laboratory data on presentation was unremarkable with normal complete blood count and normal
electrolytes except for elevated creatinine of
6.52 mg/dl and blood urea nitrogen of 64 mg/dl,
which were his usual baseline dialysis laboratory
values. The initial peritoneal dialysis ﬂuid demonstrated increased leucocyte count of 243/microliter
with neutrophil percentage high of 85%. The patient
was commenced on empiric intra-peritoneal cefazolin and ceftazidime in the clinic. Three days after
incubation, PD ﬂuid culture grew Brevibacterium
(group B) in the aerobic bottle, which was found
to be sensitive to vancomycin (minimum inhibitory
concentration 0.25 mg/mL). Broth microdilution
method (Pasco, Detroit, MI) was utilized for antibiotic susceptibility and interpretations were deciphered according to Funke et al.1 breakpoint
recommendations for Corynebacterium and associated coryneforms. The peritoneal ﬂuid culture
showed grayish white colonies with shiny surfaces,
notable for Brevibacterium species.2 16s rRNA gene
sequencing was used, as per interpretative criteria
deﬁned by the U.S. Clinical and Laboratory Standards Institute (CLSI).3 GenBank database (U.S.
National Institutes of Health, Bethesda, MD, USA),
was used along with the BLAST algorithm for
sequence alignment. 99.1% compatibility in 16S
rRNA sequence to the GenBank sequence of
the type of strain of B. casei (ATCC 35513T) was
found.
Antibiotics were changed to intraperitoneal
vancomycin for a total 3-week duration. The PD
catheter was salvaged and repeat peritoneal dialysate (PD) ﬂuid analysis after 2 weeks and 4 weeks of
completing therapy showed a WBC count of
<20 cells/micro-L. We admit there are no standard
guidelines for duration of antibiotics for these rare
species or recommendations for surveillance, but
because of rarity of this species and its nature of
complications, we opted to pursue three weeks
course to help better clearance of the micro-organism. The patient was continued on peritoneal dialysis with no modality change and did not encounter
any further complications.

3. Discussion
Peritonitis is a serious and life-threatening
complication of PD potentially leading to signiﬁcant
morbidity, catheter loss, ultraﬁltration loss,
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permanent membrane damage, transfer to hemodialysis, and death.4,5 There is a wide discrepancy of
peritonitis rate among PD patients in different
countries for reasons unknown.5 A recent multicenter study conducted worldwide in seven countries across 209 facilities, showed an overall
peritonitis rate of 0.26/patient-year, 0.35 to 0.40/patient-year in Thailand, the United Kingdom, and
Australia/New Zealand and 0.26 to 0.29/patient-year
in Canada, Japan, and the United States.6
A retrospective study demonstrated peritonitis to
be independently associated with a higher risk of
cardiovascular and all-cause mortality plus infection-related mortality in patients who have been on
peritoneal dialysis for duration beyond 2 years.7 In
the United States, approximately 62% of cases of
peritonitis are caused by gram-positive organisms
(31% being coagulase-negative Staphylococcus),
20.5% by gram-negative organisms (mostly E. coli,
Klebsiella, Pseudomonas), 3.92% by fungi, and 15.9%
reported as culture-negative peritonitis.8 Among
fungi, Candida albicans and newly emerging Candida
parapsilosis are the commonest organisms.9
Brevibacterium genus is a coryneform bacterium
with 45 different species but only 10 have been
isolated from clinical samples.10 It is a gram-positive, catalase-positive, aerobic, immobile bacterium
that is a part of the normal microbiota of the skin
and had rarely been thought to be a cause of pathology in immunocompetent human beings.10
Brevibacterium was ﬁrst described in 1953 by Dr.
Robert Breed,11 and the ﬁrst reported isolation of B.
casei from clinical cases was documented by Gruner
E et al., in 1993 from Switzerland.12 Thereafter,
Brevibaterium species have now been identiﬁed as a
cause of peritonitis in dialysis patients,13e17 catheter-related bloodstream infection,18 brain abscess,19 and endocarditis, pericarditis, osteomyelitis,
endophthalmitis, discitis. Cases of peritonitis have
been reported due to Brevibacterium otidis14 and
Brevibacterium iodinum13 and two relapsing peritonitis cases with B. casei.15,17 They are summarized in
Table 1.
Diagnosis of Brevibacterium may be challenging as
gram stain usually shows gram-positive rods like
diphtheroids. Biochemical testing could further
differentiate the organisms,20 but the gold standard
test is 16S rRNA gene sequencing to identify species.2 Brevibacterium is generally resistant to penicillin and 3rd generation cephalosporins and
sensitive to ﬂuoroquinolones and vancomycin.2 B.
casei can cause relapsing peritonitis even after
treatment with intraperitoneal antibiotics. In previously published case reports of peritonitis due to
Brevibacterium species,14,16 removal of PD catheter
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Table 1. Summary of case reports published on Brevibacterium peritonitis.
Author

Year

Location

Age/Gender

Species

Dialysis
modality

Treatment

Outcome

Modality
changed

Antonious S et sl13

1997

Greece

69/F

B iadinum

CAPD

No

2000

Belgium

73/F

B otitidis

CAPD

Improved

No

Poesen K et al.15

2012

Belgium

39/M

B casei

CCPD

Cefuroxime, then
Ciproﬂoxacin
Cefazolin plus
Genamicin
Vancomycin

Improved

Wauters G et al.14

IP
IP
IP
IP
IP

Choi JS et al.16

2012

Korea

52/M

CAPD

2014

Saudi
Arabia

33/F

IP
IP
IP
IP

Ceftazidime and
Cefazolin
Ceftazidime and
Cefazolin

Yes, switched
to HD
No

Althaf M et al.17

Species not
identiﬁed
B casei

Delayed
recovery
Delayed
recovery
Delayed
recovery

CCPD

Yes, switched
to HD

Legend: F: Female; M: Male; B: Brevibacterium; IP: Intraperitoneal; CAPD: Continuous Ambulatory Peritoneal Dialysis; CCPD:
Continuous Cycler Peritoneal Dialysis; HD: Hemodialysis.

was necessary for effective treatment of peritonitis.
In our case, the patient was treated with intraperitoneal vancomycin alone and his PD catheter was
salvaged with the effective continuation of peritoneal dialysis. International Society for Peritoneal
Dialysis guidelines recommend 2 weeks of antibiotics for most gram-positive organisms except 3
weeks for Staphylococcus and Enterococcus while 3
weeks of antibiotics for most gram-negative bacilli.5
Through our case, we suggest at least 3 weeks of IP
antibiotics would be preferable in these types of
gram-positive organisms to help ensure adequate
clearance of the organism and prevent its relapse.
Surveillance PD culture should be done in 2 weeks
and 4 weeks of recovery to ensure that this organism, which has a high rate of recurrence, doesn't
recur.
As per published data, this is only the third
reported case of peritonitis by B. casei and 6th
overall Brevibacterium species induced peritonitis.
Also, this could be the ﬁrst reported case of B. casei
peritonitis from North America. Unlike previous
cases of peritonitis caused by this organism, our
patient did not require removal of peritoneal dialysis catheter and was able to continue peritoneal
dialysis without relapse of the infection.
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